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In many countries where tuberculosis (TB) is endemic, the Bacillus Calmette–Guérin
(BCG) vaccine is given as close to birth as possible to protect infants and children from
severe forms of TB. However, BCG has variable efficacy and is not as effective against
adult pulmonary TB. At present, most animal models used to study novel TB vaccine
candidates rely on the use of adult animals. Human studies show that the infant immune
system is different to that of an adult. Understanding how the phenotypic profile and
functional ability of the immature host immune system compares to that of a mature adult,
together with the subsequent BCG immune response, is critical to ensuring that new TB
vaccines are tested in the most appropriate models. BCG-specific immune responses
were detected in macaques vaccinated within a week of birth from six weeks after
immunization indicating that neonatal macaques are able to generate a functional cellular
response to the vaccine. However, the responses measured were significantly lower than
those typically observed following BCG vaccination in adult rhesus macaques and infant
profiles were skewed towards the activation and attraction of macrophages and
monocytes and the synthesis in addition to release of pro-inflammatory cytokines such
as IL-1, IL-6 and TNF-a. The frequency of specific immune cell populations changed
significantly through the first three years of life as the infants developed into young adult
macaques. Notably, the CD4:CD8 ratio significantly declined as the macaques aged due
to a significant decrease in the proportion of CD4+ T-cells relative to a significant increase
in CD8+ T-cells. Also, the frequency of both CD4+ and CD8+ T-cells expressing the
memory marker CD95, and memory subset populations including effector memory,
central memory and stem cell memory, increased significantly as animals matured.
Infant macaques, vaccinated with BCG within a week of birth, possessed a significantly
higher frequency of CD14+ classical monocytes and granulocytes which remained
different throughout the first three years of life compared to unvaccinated age matchedorg October 2021 | Volume 12 | Article 7545891
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Frontiers in Immunology | www.frontiersin.animals. These findings, along with the increase in monokines following vaccination in
infants, may provide an insight into the mechanism by which vaccination with BCG is able
to provide non-specific immunity against non-mycobacterial organisms.Keywords: BCG, infant, immunology, macaque, infant vaccination, age comparisonINTRODUCTION
Bacillus Calmette–Guérin (BCG) is one of the most widely used
vaccines worldwide, yet the efficacy it confers is highly variable
(0-80%) (1, 2) and how it affords protection fromMycobacterium
tuberculosis (M. tb) is still not fully understood. In the UK, the
BCG vaccine is only routinely given to those at high risk of
tuberculosis (TB), but in endemic regions where the incidence of
TB is high, such as parts of Africa and Asia, BCG vaccination is
recommended as part of the neonatal vaccination programme, as
it does afford protection from severe forms of the disease such as
meningitis and miliary TB in children (2). BCG has been shown
to improve the efficacy of other neonatal vaccines and has been
linked to other beneficial effects resulting in reduced infant
mortality (3, 4). Although the BCG vaccine is routinely
administered to infants, there is little knowledge of the
influence of BCG on the neonatal immune system.
The production of IFN-g by effector cells in response to
stimulation with tuberculin purified protein derivative (PPD) is
often used as a measure of vaccine immunogenicity in clinical
trials (5). Recent studies in non-human primates (NHPs) (6)
have shown that increased frequency of IFN-g secreting cells in
response to PPD induced after vaccination significantly
correlated with decreased disease burden and improved clinical
parameters following challenge. A protective role for IFN-g in the
bovine model of TB has been suggested by Hope et al. (7), who
showed increased levels of IFN-g secreting memory T-cells post-
vaccination in BCG vaccinated calves directly correlated with
protection from disease and also, the magnitude of antigen-
specific CD4+ IFN-g cells post-challenge correlated with the
severity of the disease.
There is currently no validated correlate of protection against
M. tb infection and although IFN-g is often used as a measure to
assess vaccine immunogenicity, many studies have shown that
IFN-g, at least on its own, is not sufficient to provide protection
(8). Other cytokines associated with the Th1 and Th17
response, such as TNF-a, IL-2 and IL-17, are thought to play
an important role in protection from TB when co-expressed by
multifunctional T-cells (9). Furthermore, memory cells that
develop from T-cells with the capacity to produce multiple
cytokines have the ability to provide more durable protection
than cells producing IFN-g alone (6, 10–13). IL-17 is also
considered important in the regulation of the Th1 pro-
inflammatory response (12, 14, 15).
In human new-borns, the ability to generate an effective
inflammatory immune response to an antigen is greatly
reduced compared to adults (3, 16, 17), as well as the capacity
of CD4+ T-cells to produce IFN-g, which is likely to affect the
Th1 response induced by the vaccine (18). To prevent adverseorg 2immune reactions to maternal antigens, the fetal immune system
is kept in a state of tolerance and is widely believed to be biased
towards a Th2 response (19) with the pro-inflammatory Th1
response actively suppressed. In the period after birth, the
neonate maintains partial tolerance to limit adverse immune
reactions to antigens in the environment, and to allow
colonization of commensal microorganisms which are
beneficial to the host and help to prevent infection by
pathogenic bacteria. Unfortunately, as infants have not yet
developed a full complement of commensals, they are more
prone to infections such as TB (20–22). As the fetus develops in a
sterile environment and its pre-exposure to antigens and
pathogens is minimal, to generate an effective response to a
vaccination, a new-born must rely on its innate immune system
rather than adaptive immune response to prevent infection.
There is evidence to suggest that human infants are able to
mount an initial immune response following intradermal (ID)
vaccination to BCG. A UK clinical trial (23) has identified a
number of cytokines and chemokines involved in the generation,
proliferation and recruitment of various cell subsets after BCG
vaccination in infants. The molecules identified are involved in
the Th1, Th2 and regulatory responses, and could provide
biomarkers of protection when secreted together. Further,
more recent studies in UK infants have described a BCG-
induced, trained innate immunity response (24, 25).
The importance of understanding the infant immune
response to vaccination is illustrated by the booster vaccine,
MVA85A. When delivered to infants previously vaccinated
with BCG, the IFN-g response profiles measured using
an ELISPOT assay were lower than in similarly boosted
adults (26). As novel TB vaccines are likely to be given to
individuals previously vaccinated at birth, pre-clinical models
that accurately reflect the BCG primed infant immune system are
vital to the development and identification of new, improved,
vaccination strategies.
To date there have been few studies in which TB vaccines
have been evaluated in models using neonatal and young
animals. Prior to challenge with Simian Immunodeficiency
Virus (SIV), BCG was delivered to infant NHPs within the first
2 weeks of life (27, 28). These studies demonstrated an initial
immune response following intradermal (ID) vaccination with
BCG in infancy (responses studied for up to nine weeks after
BCG), with increases identified in the frequency, activation and
function of CD4+ T-cells and also classical monocytes using flow
cytometry and by gene expression analysis. Our study monitors
changes in the macaque immune system following BCG
vaccination given within a week of birth on the immune
system during the first three years of life and directly compares
the cellular immune response elicited by BCG in infants with thatOctober 2021 | Volume 12 | Article 754589
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the differences in the host response to BCG vaccination between
the mature and immature immune systems (29) will be critical to
the development and testing of vaccine strategies that aim to
provide improved protection and enhanced immunogenicity,
and, and which may facilitate the identification of correlates of
protection and thereby further our knowledge of how BCG
shapes the host immune system. This knowledge will inform
decision making on future vaccines that may include vaccination
in later in life with either a further dose of BCG or other
boosting vaccines.MATERIALS AND METHODS
Experimental Animals
The animals used in these studies were male and female rhesus
macaques (Macaca mulatta) of Indian genotype and obtained
from an established, closed UK breeding colony (UKHSA,
Porton Down, UK). Animals were housed in compatible social
groups, in accordance with the Home Office (UK) Code of
Practice for the Housing and Care of Animals Bred, Supplied
or Used for Scientific Purposes (2014) and the National
Committee for Refinement, Reduction and Replacement
(NC3Rs) Guidelines on Primate Accommodation, Care and
Use, August 2006. Enrichment was afforded by the provision
of high-level observation balconies, swings, deep litter to allow
foraging, feeding puzzles and toys. In addition to standard old-
world primate pellets further food was provided by a selection of
vegetables and fruit. Animals were sedated by intramuscular
(IM) injection of ketamine hydrochloride (Ketaset, 100 mg/ml,
Fort Dodge Animal Health Ltd, Southampton, UK; 10 mg/kg) for
procedures requiring removal from their housing. Study designFrontiers in Immunology | www.frontiersin.org 3and procedures were approved by the UK Health Security
Agency, Porton Down Animal Welfare and Ethical Review
Body, and authorized under an appropriate UK Home Office
project license.
Sample collection and experimental design including
application of vaccination is summarized in Figure 1 and
Supplementary Figure 1. Due to small volumes of blood
permitted for collection from the infant macaques, animals
were randomly assigned to sub-groups to enable completion of
each type of immunological analysis
Vaccination
Vaccinations were delivered as specified by the manufacturer’s
guidelines and in accordance with current clinical protocols for
application of BCG vaccination to human infants and adults
(30). New-born rhesus macaques were immunized within seven
days of birth with 50 ml Danish strain 1331 (Statens Serum
Institute (SSI), Copenhagen, Denmark) delivered to the upper
left arm by intradermal injection using a limited volume ‘insulin
syringe’. Vaccination dose was verified by culture of the residual
vaccine on Middlebrook 7H11 selective agar (between 1-6 x 106
CFU/ml, data not shown). Adult macaques were vaccinated in an
identical fashion but with 100 ml of BCG Danish strain 1331 as
specified by the manufacturer’s guidelines.
Blood Sample Collection
Macaques were sedated at regular intervals for blood sample
collection. For welfare reasons, infant macaques were not sedated
during blood sample collection until they reached an age where
their activities were comparatively independent of the mother
and of a size where safe restraint was impracticable. Blood was
collected from the femoral vein using a needle and syringe and
dispensed into heparin tubes (Sigma Aldrich, Gillingham, UK)A
B
FIGURE 1 | Study timeline relative to BCG vaccination and immunological analysis. (A) shows the study timeline in which infant rhesus macaques received BCG
delivered by intradermal injection (n = 39) within a week of birth (two to seven days after birth) or remained unvaccinated as controls (n = 20). (B) Young adult
macaques aged between 3.7 and 5.2 years of age received BCG delivered by intradermal injection at study week 0 (n = 19). Circles represent points relative to
vaccination at which clinical examinations were conducted and blood samples collected for application of immunological analyses.October 2021 | Volume 12 | Article 754589
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was calculated in line with body weight and in accordance with
the recommendations of the BVA/FRAME/RSPCA/EFAW Joint
Working Group on Refinement Recommendations for Removal
of Blood from Laboratory Animals (31).
Body weight, body temperature and red blood cell (RBC)
hemoglobin levels were measured at each time point. RBC
hemoglobin concentration was measured using a HaemaCue
haemoglobinometer (Haemacue Ltd, Dronfield, UK) and
erythrocyte sedimentation rate (ESR) was measured using the
Sediplast system (Guest Medical, Edenbridge, UK). Animal
behavior was observed daily throughout the study.
Immune Response Analysis
Interferon-Gamma (IFN-g) ELISPOT
ELISPOT assays were performed on peripheral blood
mononuclear cells (PBMC) isolated from heparin anti-
coagulated blood to measure the frequency of cells producing
Interferon-gamma (IFN-g) in response to stimulation with 10
µg/ml purified protein derivative (PPD) (SSI, Copenhagen,
Denmark) using standard methods, as previously described (6).
Quantification of Secreted Biomarkers
in Mycobacterial Antigen Stimulated
Blood Cultures
Antigen-specific secretion of a range of cytokines, chemokines
and growth factors was assessed by dilution of heparinized blood
samples 1:10 with serum free Roswell Park Memorial Institute
(RPMI) (R0) medium supplemented with L-glutamine (2 mM),
penicillin (50 U/ml) streptomycin (50 mg/ml) (all from Sigma
Aldrich, Gillingham, UK), before six day culture at 37°C, 5%
CO2, with 10 µg/ml tuberculin PPD (Statens Serum Institute,
Copenhagen, Denmark), or 10 µg/ml phytohaemmagglutinin
(PHA) from Phaseolus vulgaris (Sigma Aldrich, Gillingham,
UK) as positive control, or R0 alone as a negative control.
Following incubation, culture supernatants were aspirated
using a one ml syringe (BD Biosciences, Oxford, UK) and
passed through two 0.2 µm polyether sulfone (PES) membrane
filters (GE Life Sciences, Amersham, UK), before storage at
-80°C. Secreted biomarkers in filtered culture supernatants
were quantified using a 37-plex Procartaplex bead array assay
(Thermo Fischer Scientific, UK) applied according to the
manufacturer’s instructions for detection of the following
analytes: Eotaxin, G-CSF, GM-CSF, IFN-alpha, IFN-gamma,
TNF-alpha, IL-10, IL-12p70, IL-13, IL-15, IL-17A, IL-18, IL-
1b, IL-1RA, IL-2, IL-23, IL-4, IL-5, IL-6, IL-7, IL-8, IP-10, I-TAC
(CXCL11), MCP-1 (CCL2), macrophage inflammatory protein-
1a (MIP-1alpha), macrophage inflammatory protein-1a (MIP-
1beta) (CCL4), SDF-1alpha (CXCL12), MIG (CXCL9), CD40-
Ligand, BLC (CXCL13), BDNF, SCF, VEGF-D, bNGF, FGF-2,
PDGF-BB, VEGF-A. Culture filtrates were analyzed using a
Luminex Magpix instrument (Luminex Corporation, US)
equipped with the xPONENT 4.2 software package (Luminex
Corporation). Standard curves were generated in duplicate and
used to interpolate the concentration of each analyte. All data
below the limit of detection specified by the kit manufacturerFrontiers in Immunology | www.frontiersin.org 4were assigned a zero value. The analyte concentration measured
in negative control cultures was subtracted from antigen
stimulated samples to obtain a measure of antigen-specific
biomarker secretion and the analyte concentration was
multiplied by ten to account for the initial dilution of the
sample and provide a value per ml of blood.
Polyfunctional Intracellular Cytokine
Staining and Antigen-Specific Memory
T-Cell Assay
Intracellular cytokine staining (ICS) was performed using 1 x 106
PBMC in medium (R10) consisting of RPMI 1640 supplemented
with L-glutamine (2 mM), penicillin (50 U/ml) streptomycin (50
mg/ml) (all from Sigma Aldrich, Gillingham, UK) and 10% heat-
inactivated foetal bovine serum (Labtech Ltd, Uckfield, UK).
These cells were stimulated with a 10 µg/ml solution of CD28
and CD49d co-stimulatory antibodies (both from BD
Biosciences, Oxford, UK) and either 10 µg/ml PPD (SSI,
Copenhagen, Denmark), or 5 µg/ml staphylococcal enterotoxin
b (SEB) (Sigma Aldrich, Gillingham, UK), or R10 medium alone
as negative control, for a total of six hours at 37°C, in a 5% CO2
supplemented incubator. Following the initial two hours of
incubation, the protein transport inhibitor Brefeldin-A (Sigma
Aldrich, Gillingham, UK) was added to the incubation mixture at
a final concentration of 10 µg/ml. Following incubation, cells
were washed by centrifugation at 400g for 5 minutes with FACS
buffer consisting of PBS + 1% FCS and incubated for 30 minutes
at room temperature with optimal dilutions of the amine-
reactive Live/Dead Fixable Red viability cell stain (Life
Technologies, Renfrew, UK) and the antibodies CD4 PerCP-
Cy5.5 (BD Biosciences, Oxford, UK), CD8 BV510, CD28 BV421,
CD95 Pe-Cy7, CD56 BV605, CD16 BV785, CD14 PeDazzle594,
CD20 PeDazzle594 (all Biolegend, London, UK), CCR7 PE
(eBioscience, Hatfield, UK), CD45RA APC-Vio770, (both
Miltenyi Biotech Ltd, Bisley, UK). Following surface marker
staining, the cells were washed and then permeabilized by
incubation at room temperature for 15 minutes with Fix/Perm
reagent (BD Biosciences, Oxford, UK). Further cell washes were
applied by centrifugation using Permwash buffer (BD
Biosciences, Oxford, UK), before staining for intracellular
antigens by incubation at room temperature for 30 minutes
with the antibodies CD3 AF700, IFN-g FITC, TNF-a BUV395
(all from BD Biosciences, Oxford, UK), IL-2 APC (Miltenyi
Biotech Ltd, Bisley, UK), IL-17 BV711 (Biolegend, London, UK).
Unstimulated PBMCs were stained with CD4 PerCP-Cy5.5,
CD25 FITC (BD Biosciences, Oxford, UK), CD8 BV510, CD14
PeDazzle594, CD20 PeDazzle594 (Biolegend, London, UK),
CD127 APC (eBioscience, Hatfield, UK) to investigate CD4+
T-regulatory cells.
BD Compbeads (BD Biosciences, Oxford, UK) were labelled
with the above fluorochromes for use as compensation controls.
Following incubation with the antibodies for 30 mins in the dark
at room temperature, cells and beads were washed by
centrifugation at 400g for 5 minutes and fixed in 4%
paraformaldehyde solution (Sigma Aldrich, Gillingham, UK)
prior to flow cytometric acquisition.October 2021 | Volume 12 | Article 754589
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Using Whole Blood Intracellular
Cytokine Staining
Freshly collected blood anti-coagulated with heparin was
incubated with a solution of 0.1 µg/ml of CD28 and 0.1 µg/ml
of CD49d costimulatory antibodies (BD, Biosciences, Oxford,
UK) alone (negative control), or with PPD (10 µg/ml), or SEB (5
µg/ml) (positive control) (Sigma Aldrich, Gillingham, UK) at
37°C for 5 hours, then a further 16 hours with Brefeldin A (10ug/
mL) (Sigma Aldrich, Gillingham, UK). After incubation, 40 µl of
20 mM EDTA (Ethylenediaminetetraacetic acid solution) (Sigma
Aldrich, Gillingham, UK) was added to remove adherent cells
and after 15 minutes, red blood cells were lysed using FACS
Lysing Solution (BD, Biosciences, Oxford, UK). Cells were
washed by centrifugation at 400g for five minutes then stored
in cryomedium consisting of heat inactivated FBS (Labtech Ltd,
Uckfield, UK) with 10% dimethyl sulfoxide (DMSO) (Sigma
Aldrich, Gillingham, UK) at -196°C until required for analysis.
Following resuscitation, cells were washed by centrifugation
in FACS buffer and then incubated for 30 minutes at room
temperature with fluorescent antibodies: CD4 APC-H7, CD8
PerCPCy5.5, CD16 BV421 (all from BD Biosciences, Oxford,
UK), CD14 PE, CD20 ECD (all from Beckman Coulter, High
Wycombe, UK), CD95 BV605, HLA-DR BV785, (all from
Biolegend, London, UK) in 50 µl BD Brilliant stain buffer (BD
Biosciences, Oxford, UK). Cells were washed by centrifugation at
400g for 5 minutes before permeabilization in cytoperm/cytofix
solution (BD Biosciences, Oxford, UK) for 15 minutes, washed
by centrifugation at 400g for 5 minutes with Perm/wash buffer
(BD Biosciences, Oxford, UK) before staining with fluorescent
antibodies: CD3 AF700, IFN-g FITC, TNF-a BUV395 (all from
BD Biosciences, Oxford, UK), IL-17 BV711 (Biolegend, London,
UK), IL-2 APC, (Miltenyi Biotech, Bisley, UK), in 50 µl BD
Brilliant stain buffer (BD Biosciences, Oxford, UK) for 30
minutes at room temperature. Incubation was followed by
washing of the cells by centrifugation as described previously
with Perm/wash buffer (BD Biosciences, Oxford, UK) prior to
fixing in 4% paraformaldehyde (Sigma Aldrich, Gillingham,
UK). Cells were analyzed using flow cytometry. BD
Compbeads (BD Biosciences, Oxford, UK) were labelled with
matching fluorochromes and used as compensation controls.
Flow Cytometric Acquisition and Analysis
Cells were analyzed using a five laser LSRII Fortessa instrument
(BD Biosciences, Oxford, UK) and data were analyzed using
FlowJo (version 9.7.6, Treestar, Ashland, US). Cytokine-
producing T-cells were identified using a forward scatter-
height (FSC-H) versus side scatter-area (SSC-A) dot plot to
identify the lymphocyte population, to which appropriate
gating strategies were applied to exclude doublet events, non-
viable cells, monocytes (CD14+) and B cells (CD20+). For ICS
analysis, sequential gating through CD3+, followed by CD4+ or
CD8+ gates were used before individual cytokine gates to identify
IFN-g, IL-2, TNF-a and IL-17 producing populations.
Polyfunctional cells were identified using Boolean gating
combinations of individual cytokine-producing CD4 or CD8Frontiers in Immunology | www.frontiersin.org 5T-cells. Antigen-specific T-cell memory profiles were identified
by applying a summed CD4 or CD8 cytokine Boolean
combination, followed by gating for CD95 surface staining.
Differentiation of effector, transitional effector, central memory,
and stem cell memory T-cell populations was established by
CD45RA, CD28 and CCR7 expression patterns. The software
package PESTLE version 1.7 (Mario Roederer, Vaccine Research
Centre, NIAID, NIH) was used for background subtraction to
obtain antigen-specific polyfunctional ICS and memory T-cell
cytokine responses, Graphpad Prism (version 8.0.1) was used to
generate graphical representations of flow cytometry data.
Statistical Analyses
Data from IFN-g ELISPOT assay, multiplex cytokine release
assay and both phenotypic and multiparameter flow cytometry
assays were analyzed using GraphPad Prism Software (version
8.0 1 La Jolla, California, USA). Age-specific differences of
immune cell populations and T-cell functionality, both before
and after vaccination, were compared between each age group
using a non-parametric Mann-Whitney U-test. Similarly,
vaccine-induced changes in both cell frequency and T-cell
functional profiles were compared within the vaccination
groups using a Wilcoxon-rank test. Statistical significance was
defined as a p-value equal to or lower than 0.05.
The software package PESTLE (version 1.8) was used for
background subtraction to determine antigen-specific ICS
responses. Graphical representation and statistical analysis of the
data was performed using GraphPad Prism Software (version 8.0 1
La Jolla, California, USA). Negative values in functional data




Frequency of PPD-Specific IFN-g Secreting Cells
Measured by ELISPOT Assay
The frequency of PPD-specific IFN-g secreting cells was
evaluated in macaques vaccinated within a week of birth and
compared to unvaccinated age-matched controls. Samples were
taken at regular intervals from six weeks until 36 weeks of age.
Responses measured in BCG vaccinated and unvaccinated age-
matched macaques were compared at each time point. BCG
vaccinated macaques possessed a significantly higher frequency
of PPD-specific IFN-g secreting cells at weeks six (p = 0.0203), 12
(p = 0.0001), 16 (p = 0.0093) and 20 (p = 0.0012) than those who
did not receive the vaccine. The level of response was not
significantly different between the vaccination groups at week
28 and 36 indicating that the frequency of PPD-specific IFN-g
secreting cells had returned to a level equivalent to unvaccinated
control animals (Figure 2A). The young adult animals had a
significantly higher frequency of antigen-specific IFN-g secreting
cells at all time points following BCG vaccination compared to
those vaccinated at birth (p < 0.0001) (Figure 2B).October 2021 | Volume 12 | Article 754589
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Measured by Cytokine Bead Array
Supernatants from PPD-stimulated cultures of whole blood
collected at 12, 16 and 20 weeks after neonatal vaccination
with BCG from seven infant macaques were evaluated for the
presence of 37 cytokines, chemokines and growth factors to
identify vaccine-specific responses and compared that of
unvaccinated animals. Due to limited blood volumes
permissible for collection from the infant animals, samples
were not available for the unvaccinated animals at each
equivalent time point to the BCG vaccinated infants. An
average was taken of the two earliest time points available
from unvaccinated infant macaques (all before 20 weeks of
age). Of the 37 analytes measured, the concentration of 27 (IL-
2, IL-4, IL-5, BLC, IL-7, IL-8, IL-10, IP-10, MCP-1, SDF-1a,
Eotaxin, IL-12p70, IL-13, IL-17A, IL-18, sCD40L, G-CSF, GM-
CSF, I-TAC, IFN- a, IL-15, VEGF-D, bNGF, BDNF, PDGF-BB,
FGF-2 and VEGF-A) were either undetectable (below the limit of
detection of the assay system), or did not differ from the
unvaccinated age-matched controls following BCG vaccination.
The concentrations of the remaining ten analytes were
significantly higher in the group that received a BCG
vaccination in comparison to unvaccinated age-matched
controls. Secretion of the pro-inflammatory cytokine TNF-a
was significantly higher at weeks 12, 16 and 20 (p = 0.0332 for
all time points) than in macaques that had not received BCG
(naïve). The BCG vaccinated group also had significantly higher
concentrations of IL-1 at week 12 (p = 0.0064), week 16 (p =
0.0495) and week 20 (p = 0.0495); IL-6 at week 12 (p = 0.0216);
IL-23 at week 20 (p = 0.05); and IFN-g at week 12 (p = 0.0047)
and week 16 (p = 0.0023). Chemokine markers MIP-1a, MIP-1b
and MIG which are typically produced by macrophages and
monocytes were significantly increased in BCG vaccinated
macaques compared to unvaccinated age matched controls at
12 weeks (MIP-1a: p = 0.0222, MIP-1b: p = 0.0047) and 20 weeksFrontiers in Immunology | www.frontiersin.org 6(MIP-1a: p = 0.05, MIG: p = 0.05). Modulatory cytokines IL-
1RA and SCF were also significantly increased in the vaccinated
group at week 12 (p = 0.0167) and week 20 (p = 0.0216),
respectively (Figure 3A).
The concentration of analyte secreted in response to PPD-
stimulation measured after BCG vaccination in infants was
compared to that secreted into whole blood cultures prepared
from similarly vaccinated adult macaques at weeks 12, 16 and 20
after receiving the BCG vaccine. The concentration of cytokine
produced in response to antigenic stimulation in samples
collected before vaccination in the adult group was compared
to the concentration secreted by unvaccinated infant macaques.
As before, the presence of 37 cytokines, chemokines and growth
factors to identify vaccine-specific responses were evaluated and
compared. Of the 37 analytes measured, the concentration of 24
cytokines, chemokines and growth factors were found to
significantly increase after BCG was given to adult macaques.
Of the ten analytes that were significantly increased after
vaccination in the infant vaccinated group, the concentrations
of four IL-1b, IL-23 SCF and Eotaxin were uniquely found to be
significantly higher after BCG vaccination in the infant group
only, whereas 19 analytes; MCP-1, MIP-1b, I-TAC, SDF-1a,
BLC, IL-2, IL-4, IL-5, IL-7, IL-8, IL-10, IP-10, IL-12p70, IL-13,
IL-15, IL-17A, IL-18, VEGF-D, PDGF-BB and FGF-2 were
significantly increased after vaccination in the adult vaccinated
group only. PPD-specific secretion of eight chemokines; MIG,
MCP-1, MIP-1b, IL-8, I-TAC, SDF-1a and BLC was found to be
significantly higher following BCG vaccination in the adult
group compared to the infant group (p < 0.05). The
concentrations of growth factor, FGF-2 and cytokines IL-4, IL-
5, IL-15 and TNF-a were also found to be significantly higher
(p < 0.05 or close to significance, p = 0.0699, for IL-17A) after
vaccination in the adult group. There was a trend (p = 0.0699) for
IL-23 to be increased at both week 12 and 16 after BCG in the
infant vaccinated group compared to the adult group. EotaxinA B
FIGURE 2 | PPD-specific IFN-g spot forming unit (SFU) frequency measured by ELISPOT following ID BCG vaccination. (A) IFN-g-specific SFU from BCG vaccinated
macaques and unvaccinated macaques during the initial 36 weeks after vaccination. (B) IFN-g-specific SFU from BCG vaccinated infant (pink) and young adult (blue)
macaques during the first 20 weeks after vaccination. Box plots show the group median +/- the inter-quartile range measured at each time point after vaccination, with
minimum and maximum values connected by whiskers. Significant differences measured by Mann-Whitney U-test between the groups are indicated. *p ≤ 0.05, **p <
0.01, ****p < 0.0001, NS, not significant. n=39 for BCG vaccinated (pink), n=20 for unvaccinated controls (grey) and n=19 for young adults (blue).October 2021 | Volume 12 | Article 754589
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FIGURE 3 | PPD-specific secretion of cytokine, chemokine and growth factor biomarkers measured in whole blood culture supernatant. Box plots (A) show the
group median titre of each cytokine, chemokine or growth factor +/- the inter-quartile range measured in naïve (grey) infant macaques or at weeks 12, 16 and 20
after vaccination (pink), with minimum and maximum values connected by whiskers. Box plots (B) show the group median titre of each cytokine, chemokine or
growth factor +/- the inter-quartile range measured in naïve infant macaques (pink) or naïve adult macaques (blue) at 12, 16 and 20 weeks after vaccination in each
age group, with minimum and maximum values connected by whiskers. Dots represent individual animals. Significant differences measured by Mann-Whitney U-test
between the groups are indicated. *p ≤ 0.05, **p < 0.01, ***p < 0.001. (C). Quantity of PPD-specific secretion of cytokine, chemokine and growth factor biomarkers
between weeks 12 and 20 (AUC) in stimulated supernatants in macaques vaccinated as infants and adults in a heat map plot. Data was normalized to give a
proportional (%) representation of AUC values calculated from the profile of each analyte relative to the maximal amount of each analyte measured.Frontiers in Immunology | www.frontiersin.org October 2021 | Volume 12 | Article 7545897
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vaccination (p = 0.0210) in the macaques vaccinated within a
week of birth. Both the macaques vaccinated in infancy and those
vaccinated in adulthood showed significantly higher
concentrations of IL-6, MIG, MIP-1a, MIP-1b, TNF-a and
IFN-g after BCG vaccination. However, IL-6, MIG, MIP-1b
and TNF-a were detected at significantly higher concentrations
in the adult vaccinated group (Figure 3B).
To evaluate the total amount of PPD-specific secretion of
cytokine, chemokine and growth factor biomarkers after BCG
vaccination in macaques vaccinated within a week of birth or as
adults, the area under the curve (AUC) between weeks 12 and 20
after vaccination was calculated and represented as a heatmap
(Figure 3C). More analytes were detected at a higher
concentration in the adult vaccinated animals compared to
those vaccinated in infancy. These included both pro- and
anti-inflammatory chemokines and cytokines. Vaccinated
infants secreted higher concentrations of immunomodulatory
cytokines IL-1RA and SCF.
Age Related Change in Lymphocyte and
Memory T-Cell Populations
Lymphocyte population and subset frequencies were
characterised in macaques after BCG vaccination and in naïve
age-matched controls, to determine the impact of age on T cell
status and the evolution of T-cell memory. Immunophenotyping
was applied to cryopreserved PBMC collected at regular intervals
from nine naïve macaques between the age of six weeks and three
years along with PBMC from eight naïve macaques age four to
five years of age to determine the frequency of CD3+, CD4+,
CD8+ and CD4+CD8+ T-cells and also CD4+ and CD8+ memory
T-cell subpopulations. Memory cells were identified by their
phenotypic markers by gating on either the CD4+ or CD8+
populations with high surface staining for CD95. Central and
effector memory T-cells were identified by their differential
expression patterns of the co-stimulatory receptor CD28 and
lymph node homing marker CCR7 (32, 33). T-cell memory
phenotype was determined on CD95+ cells as CD28+CCR7+
central memory (TCM), CD28+CCR7− transitional effector
memory (TEM1) and effector memory (TEM2) CD28-CCR7−.
Stem cell memory CD28+CCR7+ CD45RA+ (TSCM) and
terminal effector memory cells CD28-CCR7- CD45RA+ (TTE)
were also investigated (Supplementary Figure 2).
The frequency of CD3+ cells did not significantly change as
the macaques matured through the first three years of life.
However, the group of young adult macaques had a
significantly lower frequency of CD3+ T-cells compared to that
measured in the longitudinal study cohort at six weeks of age.
As naïve new-born macaques progressed through the first 12
weeks of life, the frequency of both CD4+ and CD8+ T-cells
remained stable. A significant decline in the CD4:CD8 ratio
occurred during the first year of life (p = 0.0078), due to a
significant decrease in CD4+ T-cells and a significant increase in
CD8+ T-cells, but thereafter remained stable throughout
adolescence to three years of age. The CD4:CD8 ratio
measured in the young adult group was significantly lowerFrontiers in Immunology | www.frontiersin.org 8than that measured in the cohort of growing macaques at week
six (p = 0.0002), week 12 (p <0.0001), one year (p = 0.0037), two
years (p = 0.0047) and three years (p = 0.0206) which suggests
that the cell populations present in the host continue to change as
macaques age (Figures 4A–E).
The CD4+ and CD8+ T-cells present in infants were found to
have a predominantly naïve phenotype lacking the memory
marker CD95. Expression of the FAS signaling receptor CD95,
a common marker of T-cell maturation/memory status (34) did
not change between six and 12 weeks of age. Subsequently, the
frequency of CD95 expressing memory cells significantly
increased in both the CD4+ and CD8+ T-cell populations
(Supplementary table 1) over the first five years of life.
(Figures 4F, G).
The frequency of almost all CD4+ and CD8+ memory subsets
(Supplementary Figures 3A–L) significantly increased as the
macaques aged. The frequency of CD8+ TSCM, measured in the
cohort of growing macaques over the first three years of life was
significantly lower than that measured in the older group of
young adults (comparison to six week old: p = 0.0019; 12 week
old: p = 0.0055, one-year old: p = 0.0016; two-year-old: p = 0.02)
(Supplementary Figure 3K). Only low levels of CD4+ effector
memory (TEM2) cells and terminally differentiated (TTE) cells
were present in infant macaques at six or 12 weeks of age
(Supplementary Figures 3I, J).
Immunophenotyping was also applied to PBMCs collected
from seven macaques vaccinated within a week of birth in order
to investigate the impact of BCG on the evolution of lymphocytes
and T-cell memory. Different memory cell subsets, including
effector memory and central memory T-cell subsets were
compared. The frequency of CD8+ TTE cells was found to be
significantly higher in the unvaccinated macaques at two years of
age compared to those who were vaccinated in infancy (p =
0.0260) (Supplementary Figure 4P). BCG did not affect the
frequencies of lymphocytes or other memory cell subsets present
as macaques aged (Supplementary Figure 4).
To further investigate the impact of age on the immune
response elicited by BCG on memory cell populations, multi-
parameter ICS staining was applied to PBMCs collected from the
seven macaques vaccinated within a week of birth, nine
unvaccinated infant age matched controls and eight young
adult animals. The frequency of cells producing the cytokines
IFN-g, TNF-a, IL-2 and IL-17 were measured just prior to BCG
vaccination (week 0) and at week six and 12 after vaccination in
the young adult macaque group to provide a direct comparison
to the macaques vaccinated within a week of birth. Due to the age
at vaccination, the collection of blood samples prior to BCG was
not possible for the neonatally vaccinated group, therefore, the
first samples collected from unvaccinated macaques at six weeks
of age were used to represent the immune responses in infants
before vaccination. There was significantly more cytokine
produced by CD4+ memory (CD95+) cells at week six (p =
0.0007) and week 12 (p = 0.0082) and also at week six (p =
0.0310) in the CD8+ memory cells in the macaques vaccinated as
young adults compared to those vaccinated within a week of
birth (Figures 5A, B). The frequency of CD4+ cells producingOctober 2021 | Volume 12 | Article 754589
Sarfas et al. Characterization of Infant BCG VaccinationIFN-g (week six: p = 0.0130, week 12: p = 0.0047), IL-2 (week six:
p = 0.0007, week 12: p = 0.0007) and TNF-a (week six: p =
0.0210) in BCG vaccinated adults was significantly higher than in
infants. The frequency of CD8+ cells producing IFN-g (week six:
p = 0.0210) and TNF-a (week six: p = 0.05) in BCG vaccinated
adults was significantly higher than in infants (Figures 5C, D).
Age Related Changes in Composition of
the Cellular Immune Compartment in
Whole Blood
The frequency of white cell populations in the peripheral
blood of six naïve neonatal macaques was assessed by
immunophenotyping applied at the earliest opportunity that
sufficient blood volume could be collected (12 weeks of age),
then at 16 weeks and 20 weeks of age, then yearly until the
macaques reached three years of age. Population frequencies
were compared to those measured in 14 young adult macaques
aged between 3.7 and 5.2 years to identify age-associated changes
in the host.
T and B-cells were identified by their size and granularity
scattering properties using a forward scatter-area versus side
scatter-area dot plot, to which an appropriate step by step
gating strategy was applied to exclude doublet cells. B-cells,
T-cells , CD4+ and CD8+ T-cells were identified by
their expression of CD20, CD3, CD4 and CD8 markers
respectively (Supplementary Figure 5). In line with the resultsFrontiers in Immunology | www.frontiersin.org 9of intracellular cytokine staining studies of PBMCs described
above, the frequency of the CD3+ lymphocyte population did not
change and a significant decline in the CD4:CD8 ratio was
identified as macaques matured (data not shown). The
frequency of total lymphocytes did not change over the first
three years of life. However, young adult macaques had a
significantly lower number than macaques aged 20 weeks (p =
0.0154), one (p = 0.0154), two (p = 0.0247) and three (p = 0.0117)
years of age (Figure 6A). The frequency of the B-cell population
remained relatively consistent as the new-born macaques
progressed through the first 20 weeks of life, and as animals
matured over the first 3 years of life levels aligned with those
determined in the group of young adult males. However, a peak
in cell numbers was identified at two years of age when levels
reached a significantly higher frequency than those seen at 12
weeks after birth (p = 0.0313), one year (p = 0.0313), and almost
reached significance at three years of age (p = 0.0625) as animals
matured. Similarly, the frequencies recorded at two years of age
were significantly greater than those measured in the young adult
macaque group (p = 0.0487) (Figure 6B). Activated T-cells were
identified by their phenotypic markers by gating on either the
CD4+ or CD8+ populations with high surface staining for
activation marker HLA-DR (Supplementary Figure 5). A
significant increase between weeks 12 and 16 (p = 0.0313),
followed by a continued trend for an increase between weeks
16 and 20 (p = 0.0625) in the proportion of CD4+ and CD8+ cellsA B C D
E F G
FIGURE 4 | Age related changes in lymphocyte and memory cell subset populations. Plots (A–D) show the frequency of lymphocytes subsets, (E) proportions of
CD4+, CD8+ and CD4+CD8+ lymphocytes (F) CD4+CD95+ and (G) CD8+CD95+ memory cells measured in naïve macaques from infancy (6 weeks of age) through
to three years (grey) compared with young adult macaques aged between 3.7 and 5.2 years of age (blue). Box plots show the group median +/- the inter-quartile
range, with minimum and maximum values connected by whiskers. Significant differences measured by Wilcoxon matched-pairs rank test or Mann-Whitney U-test
between the groups are indicated. *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.October 2021 | Volume 12 | Article 754589
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first 5 months of life, potentially due to contact with
environmental bacteria and viruses such as mycobacteria and
cytomegalovirus (CMV) (35–37) (Figures 6C, D). Thereafter,
the frequency of cells expressing activation marker HLA-DR did
not change significantly as macaques progressed from infancy to
early adulthood. Natural killer (NK) T-cells were identified by
gating on the CD3 population that also expressed surface marker
CD16 (Supplementary Figure 5). The frequency of NK T-cells
significantly increased between the age of week 12 and 16 (p =
0.0313) and at one year of age (p = 0.0313). There were
significantly more NK T-cells present in young adults
compared to the level present at 12 weeks of age (p = 0.05). In
contrast to the number of NK T-cells detected which declined
between the age of 1 and 3 years (p = 0.0313) (Figure 6E).
Granulocytes were identified by their size and granularity
scattering properties using a FSC-A vs SSC-dot plot with
eosinophils and neutrophils differentiated by expression ofFrontiers in Immunology | www.frontiersin.org 10CD14 and HLA-DR (Supplementary Figure 6). As the new-
born macaques progressed through the first 20 weeks of life, the
frequency of granulocytes remained consistent. However, within
the granulocyte population, the frequency of eosinophils
significantly increased (p = 0.0313), and the frequency of
neutrophils significantly decreased (p = 0.0313). As the
frequency of lymphocytes remained stable during this period,
this led to a trend for a decrease in the ratio of neutrophils
to lymphocytes (p = 0.0625). Although the frequency of
granulocytes did not significantly change over the first three
years of life in the infant macaques cohort, a significantly higher
frequency of granulocytes was measured in the group of young
adult macaques (12 weeks of age: p = 0.0256; 16 weeks of age: p =
0.05; 20 weeks of age: p = 0.0002; one year: p = 0.0023; 3 years of
age: p = 0.02). The frequencies of lymphocytes and neutrophils
remained constant over the first few years of life but there were
significantly lower numbers of lymphocytes measured in the
group of young adult macaques (close to birth: p = 0.0154; oneA B
C
D
FIGURE 5 | PPD-specific cytokine production by CD4 and CD8 memory T-cells. Total PPD-specific cytokine production by CD4+ and CD8+ T-cells. Dots represent
the summed frequency of CD4+ (A) and CD8+ (B) T-cells producing IFN-g, IL-2, TNF-a and IL-17 and CD4+ (C) and CD8+ (D) T-cells producing cytokines IFN-g,
IL-2, TNF-a and IL-17 measured in PBMCs collected from individual infant (pink) and adult (blue) animals prior to and following ID BCG vaccination. Box plots show
the group median +/- the inter-quartile range, with minimum and maximum values connected by whiskers. Significant differences measured by Mann-Whitney U-test
between the groups are indicated. *p ≤ 0.05, **p < 0.01, ***p < 0.001.October 2021 | Volume 12 | Article 754589
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age. This resulted in a significantly higher neutrophil to
lymphocyte ratio (N:L) compared to one and three-year-old
macaques (p = 0.0256). The frequency of eosinophils was also
significantly decreased in the group of young adults compared to
the levels measured in the infants macaques as they matured (12
weeks of age: p = 0.0154; 16 weeks of age: p = 0.0256; 20 weeks of
age: p = 0.0023) but not different from the macaques as they
matured from one year to three years (Figures 6F–I).
Monocytes were identified by their size and granularity
scattering properties using a FSC-A vs SSC-A dot plot, to
which a gating strategy was applied to exclude B lymphocytesFrontiers in Immunology | www.frontiersin.org 11(CD20+) and NK cells (CD8+). Cells expressing CD14 and
HLA-DR were then selected and monocyte sub-populations
were differentiated by expression of CD14 and CD16
(Supplementary Figure 7). The overall frequency of
monocytes did not show any significant changes as the
macaques progressed through life (Figure 6J).
Although the frequency of monocytes did not change
throughout the first five years of life, the significant decrease in
lymphocytes (Figure 6K) in the young adults caused the
monocyte to lymphocyte ratio (M:L) to significantly increase in
this age group (12 weeks of age: p = 0.0256; 16 weeks of age: p =
0.0408; 20 weeks of age: p = 0.0154; one year: p = 0.0117; 2 yearsA B C D E
F G H I J
K L M N
P Q R S T
O
FIGURE 6 | Age related changes in white cell populations measured in whole blood. Plots show the frequency of (A) All lymphocytes, (B) B-cells, (C) activated CD4+
and (D) CD8+ T-cells, (E) NK T-cells, (F) Granulocytes, (G) Neutrophils, (H) Eosinophils, (I) Neutrophil: Lymphocyte (N:L) ratio, (J) All monocytes, (K) Monocyte:
Lymphocyte (M:L) ratio, (L) Classical monocytes (M) Intermediate monocytes and (N) Non-classical monocytes. (O) Bars represent median values of monocyte subset
populations. (P) Natural killer cells, (Q) CD16+ NK cells, (R) CD16+CD56+ NK cells, (S) CD16-CD56+ NK cells and (T) Bars represent median values of NK cell subsets.
Cell frequency populations were measured in naïve macaques from infancy through to three years (grey) compared with young adult macaques aged 3.7 and 5.2 years of
age (blue). Box plots show the group median +/- the inter-quartile range, with minimum and maximum values connected by whiskers. Significant differences measured by
Wilcoxon matched-pairs rank test or Mann-Whitney U-test between the groups are indicated. *p ≤ 0.05, **p < 0.01, ***p < 0.001.October 2021 | Volume 12 | Article 754589
Sarfas et al. Characterization of Infant BCG Vaccinationof age: p = 0.0046, 3 years of age: p = 0.0015). The frequency of
classical (CD14+) monocytes showed a trend to decrease (p =
0.0625) during the first 20 weeks after vaccination, while the
frequency of non-classical monocytes, which are involved in T-
cell stimulation and inflammatory cytokine release (38), showed
a trend (p = 0.0625) to increase over the same period of time. The
frequency of CD16+ non-classical (CD16+) monocytes continued
to increase (p = 0.0313) until the age of two before decreasing as
macaques reach adulthood (p = 0.0313). Coincident with this,
the frequency of classical monocytes continued to decrease (p =
0.0313) significantly between the ages of one and two (p =
0.0313), until two years of age and then significantly increased
as macaques reached age five (compared to at 20 weeks of age:
p = 0.0408; 2 years of age: p = 0.0015; 3 years of age: p = 0.0046).
Significantly higher frequencies of intermediate (CD14+CD16+)
monocytes were identified in the group of young adult macaques
than in the cohort of growing macaques when 12 weeks (p =
0.0408), 16 weeks (p = 0.0326), 20 weeks (p = 0.0256), or three
years (p = 0.0162) of age. (Figures 6L–O).
NK cells were identified by gating on lymphocytes and then
excluding doublet cells, dead cells, B lymphocytes (CD20+) and
monocytes (CD14+) after which cells were sequentially gated on
their lack of CD3 (CD3-). NK cells were identified by their CD8,
CD16 and CD56 expression (Supplementary Figure 7).
Similarly to the monocytes, the total frequency of NK cells did
not show any significant changes as the macaques aged, although
infant macaques had significantly more CD56+ NK cells,
typically thought to be cytokine-producing, than macaques
aged one year, two years, three years (p = 0.0313) and five
years (p = 0.0426) of age (Figures 6P–T). The frequency of T-
regulatory cells did not significantly change in the infant cohort
during the initial 20 weeks of life, or as they aged to three years,
and the frequencies were similar to those measured in the young
adult macaque group (data not shown).
The Impact of BCG Vaccination on
the Innate Immune Cells of
Neonatal Macaques
The frequency of cell populations measured in peripheral whole
blood in a subset of six BCG vaccinated macaques was monitored
at intervals over the first three years of life alongside six
unvaccinated age-matched controls to investigate the influence
of BCG vaccination on the cellular immune compartment.
There was a non-significant trend (p = 0.0628) for a higher
frequency of total monocytes to be present in the whole blood of
macaques after vaccination with BCG compared to those who
did not receive the vaccine (Figure 7A). A significantly higher
frequency of classical monocytes was measured in the BCG
vaccinated infants at week 20 (p = 0.0260), one year (p =
0.0238) and two years (p = 0.0022) of age compared to the
level seen in the unvaccinated group. Conversely, naïve
macaques possessed a significantly higher frequency of
immunomodulatory non-classical monocytes at 16 weeks (p =
0.0260), 20 weeks (p = 0.0152) and two years (p = 0.0022) of age.
At 16 weeks of age there was also a significantly higher frequency
of intermediate monocytes (p = 0.0368) in the unvaccinatedFrontiers in Immunology | www.frontiersin.org 12macaques which continued at two years of age (p = 0.0649)
(Figures 7B–D).
BCG vaccinated infants possessed a significantly higher
frequency of granulocytes (Figure 7E) at week 20 (p = 0.0152
and two years (p = 0.0087), and also a trend at one year (p =
0.0649) of age compared to the naïve macaques. The frequency of
total lymphocytes (Figure 7F) decreased in proportion to the
increase of granulocytes in the vaccinated group at two years of
age, which was not seen in the naïve macaques. Although
differences in the frequency of neutrophils (data not shown)
between the vaccinated and unvaccinated animals did not reach
significance, the decrease in lymphocytes in the vaccinated
macaques accounted for a significantly higher neutrophil to
lymphocyte ratio (Figure 7G) at two years of age (p = 0.0260)
and also in the monocyte to lymphocyte ratio (Figure 7H).
The frequency of NK cells present in macaques that received
BCG close to birth was significantly lower (p = 0.0368) 20 weeks
after vaccination compared to the unvaccinated controls
(Figure 7I). Twelve weeks after BCG, vaccinated macaques
had a significantly higher frequency of CD16+CD56+ NK cells
present in the periphery (week 12: p = 0.0087, week 20: p =
0.0260), while the frequency of CD16+CD56- NK cells was
significantly lower (week 12: p = 0.0411). Three years after
vaccination, a significantly higher (p = 0.0260) frequency of
double positive (CD16+ CD56+) NK cells remained. There was
also a trend (p = 0.0628) for an increased frequency of CD16-
CD56+ NK cells in the BCG vaccinated infants 20 weeks after
vaccination (Figures 7J–L). The frequencies of eosinophils,
T-cells, CD4+ or CD8+ T-cells, activated lymphocytes, B-cells,
T-regulatory cells or neutrophils were not changed by
administration of the BCG vaccine (data not shown).
To further investigate the effect that age at the time of
vaccination had on the immune response to BCG, the quantity
of cytokine produced by the total NK and monocyte populations
was assessed. Multi-parameter ICS staining was applied to
stimulated whole blood collected from the six macaques
vaccinated within a week of birth, six unvaccinated infant age
matched controls and eight young adult animals. The
frequencies of cells producing the cytokines IFN-g, TNF-a,
IL-2 and IL-17 were measured just prior to BCG vaccination
(week 0) and at week 12, 16 and 20 weeks after vaccination in the
young adult macaque group to provide a direct comparison to
the macaques vaccinated within a week of birth. Due to their
young age at vaccination, blood sample collection prior to
vaccination was not possible for the neonatally-vaccinated
group Therefore, the first samples collected from unvaccinated
macaques at 12 weeks of age were used to represent the immune
responses in infants before vaccination.
The frequency of NK cells producing IFN-g (p = 0.0154) and
TNF-a (p = 0.0369) was significantly higher at 12 weeks after
vaccination in the adult vaccinated group compared to the infant
vaccinated group. Macaques vaccinated shortly after birth
possessed a significantly higher frequency of NK cells
producing IL-2 (p = 0.0168) 16 weeks after vaccination
compared to those vaccinated as adults. Comparison of
summed frequencies of cytokine producing NK cells collectedOctober 2021 | Volume 12 | Article 754589
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significantly more cytokine than those from the cohort
vaccinated as infants (p = 0.0094). However, area under the
curve analysis (AUC) of the cytokine producing cells during the
vaccination phase (12 to 20 weeks following vaccination)
indicated equivalence between the two age groups (Figures 8A,
C–F).
The frequency of functional monocytes producing IFN-g (p =
0.0154) or TNF-a 20 weeks after vaccination (p = 0.0361) was
significantly higher in the adult vaccinated group in concordance
with the findings of area under the curve analysis (AUC) of the
vaccination phase (IFN-g: p = 0.05, TNF-a: p = 0.0064)
(Figures 8B, G, H).Frontiers in Immunology | www.frontiersin.org 13DISCUSSION
In endemic regions, BCG is given to infants near to birth, but
most pre-clinical TB vaccine studies use adult animals (26).
Understanding the host response to BCG vaccination in both a
mature and an immature immune system is essential to
understand how BCG and new vaccine strategies can induce
immunity and provide protection. This knowledge will also
provide insight into the most appropriate pre-clinical models
to use for the assessment of vaccines designed to work in infants.
The systemic cellular immune response to BCG delivered
intradermally in macaques that have reached adulthood has
previously been described (10, 11). In this study, we set out toA B C D
E F G H
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FIGURE 7 | The effect of BCG on the development of whole blood cell populations in neonatal macaques. Plots show the median frequency of (A) total monocytes,
(B) classical monocytes, (C) intermediate monocytes, (D) non-classical monocytes, (E) granulocytes, (F) Total lymphocytes, (G) neutrophil: lymphocyte ratio (N:L) (H)
monocyte: lymphocyte ratio (M:L) (I) total natural killer cells (J) CD16+ NK cells (K) CD16+CD56+ NK cells and (L) CD56+ NK cells from infancy (12 weeks of age)
through to three years in macaques vaccinated within a week of birth (pink) and unvaccinated age-matched controls (grey). Plots show the group median +/- the
inter-quartile range. Significant differences measured by Mann-Whitney U-test between the groups at each time point are indicated in black. *p ≤ 0.05, **p < 0.01.October 2021 | Volume 12 | Article 754589
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mature and to evaluate the immunological response induced in
rhesus macaques when BCG is delivered within a week of birth to
further our understanding of how BCG shapes the immune
system in the initial weeks after vaccination and also long term,
and also how the infant is able to respond with an immature
immune system.
As shown by the increased frequency of IFN-g secreting cells
and the levels of cytokines and chemokines quantified by
multiplex bead array, BCG-specific immune responses were
elicited following vaccination in macaques vaccinated within a
week of birth. This indicates that although infant macaques are
documented to have a ‘naïve’ immune system with many
reporting dampened inflammatory responses (16, 22, 39), theseFrontiers in Immunology | www.frontiersin.org 14cells are able to generate a functional response to the vaccine.
However, these responses are lower than responses typically
observed in BCG vaccinated adult macaques. This reduced
immunogenicity is consistent with profiles measured in BCG
vaccinated human populations (26) where BCG is known to
provide protection from severe forms of childhood disease. It
may be hypothesized that the naïve immune system allows the
BCG vaccine to persist and continuously stimulate the immune
system to provide protection but is eventually cleared by the
immune cells present as an adult which leads to the waning of
protection (40).
To understand the response induced by BCG when delivered
in infancy, we characterised the host cell immune status as
macaques developed from six to 12 weeks after birth, throughA B
C D E
F G H
FIGURE 8 | PPD-induced cytokine production by NK cells and monocytes. Total PPD-induced cytokine production by (A) NK cells and (B) monocytes. Dots
represent the AUC of cells producing IFN-g, IL-2, IL-17, TNF-a and summed frequencies of cytokine producing cells measured in stimulated whole blood collected
from individual infant (pink bars) and adult (blue bars) animals between weeks 12 and 20. Plots show the frequency of (C) IFN-g, (D) IL-2, (E) TNF-a and (F) Total
summed cytokine produced by NK cells and (G) IFN-g and (H) TNF-a produced by monocytes prior to and following ID BCG vaccination. Box plots show the group
median +/- the inter-quartile range, with minimum and maximum values connected by whiskers. Significant differences measured by Mann-Whitney U-test between
the groups are indicated. *p ≤ 0.05, **p < 0.01.October 2021 | Volume 12 | Article 754589
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between 3.7 and 5.2 years of age. As previously shown (28, 41),
the frequency of immune cells changed as the infants developed
through the first few years of life, and in comparison to immune
cell frequencies measured in a separate group of young adult
macaques. Notably, the frequency of both CD4+ and CD8+ T-
cells expressing memory marker CD95 increased as the
macaques aged. This is likely to be a consequence of
accumulated antigen exposure as the macaque’s immune
system encounters environmental antigens and pathogens
which drives T-cell maturation and promotes a significant
increase in the frequency of CD95+ T-cells over time. The
significantly lower production of pro-inflammatory cytokines
such as IFN-g, TNF-a, IL-2 and IL-6, measured using ELISPOT,
multiplex bead array and intracellular staining assays, seen in the
vaccinated infants compared to that of an immunologically
mature adult may be due to the infant immune system
comprised predominantly of naïve immune cells. It is widely
believed that BCG predominantly mediates immunity by the
development of antigen-specific memory T cells (42), and naïve
cells (CD95-) are unable to respond to antigen by producing
cytokine. Therefore, it is perhaps unsurprising that BCG given to
infants within a week of birth generated a lower magnitude of
response when compared to similarly vaccinated adult macaques.
The effect of BCG delivered in infancy on the cellular immune
compartment may manifest overtime, for example, a significant
decrease in the lymphocyte population which affected both the
N:L and M:L ratios was observed, together with a significantly
higher frequency of CD8+ TTE cells in the macaques two years
after vaccination. Age related changes independent of BCG
vaccination were also observed as the macaques reached two
years old, B-cells were found to significantly increase while T
cells decreased. As these changes coincided with the point at
which the macaques were weaned from their mother, it suggests
that external life factors may also influence the composition of
the immune system and contribute to inflammatory effects of the
vaccine making this an area that requires further investigation.
The concentration of chemokine markers MIP-1a, MIP-1b
and MIG, typically produced by macrophages and monocytes
after stimulation, were significantly increased in macaques
vaccinated in infancy compared to unvaccinated age-matched
controls. These markers are considered important for responses
to fight infection and control inflammation. These chemokines
affect monocytes, T-cells, dendritic cells, NK cells, activate
granulocytes and induce the synthesis and release of pro-
inflammatory cytokines such as IL-1, IL-6 and TNF-a from
macrophages (43, 44) which were also significantly increased in
the vaccinated infants. Data from the immunophenotyping also
showed that BCG vaccination significantly affected the frequency
of the monocyte, granulocyte and NK cell subsets in infants
which is indicative of an innate-like, trained immune response
being induced by BCG, as previously reported in adults (24).
Classical monocytes are known for their antigen presenting
and phagocytic abilities, which may be responsible for the
increase in the frequency of this population in the macaques
vaccinated in infancy. There is evidence that BCG causes longFrontiers in Immunology | www.frontiersin.org 15term non-specific effects on the host immune system including
increased expression of pattern recognition receptors such as
CD14 (45) which can be seen in these data. The M:L ratio was
found to be significantly higher in young adult macaques
compared to macaques aged between 12 weeks and three years
of age. As an elevated M:L ratio has been associated with the risk
of subsequent tuberculosis disease (46), this may suggest the
young adults have an increased risk of developing disease
compared to infant macaques.
BCG vaccination of infant humans induces activation of
innate effector cells such as NK cells (24). Here we found that
cytokine producing CD56+ NK cells were present at a
significantly higher frequency in 12 week old macaques
compared to young adults and these were significantly
increased after vaccination in infant macaques. CD56+ NK cell
subsets have a higher capacity to produce cytokines following
activation by monocytes which suggests that a trained immunity
phenotype, characterized by an increased capacity to produce
proinflammatory cytokines, is being induced in infants when
vaccinated shortly after birth.
There was also significantly more antigen-specific production
of the modulatory cytokines IL-1RA and SCF in the infant BCG
vaccinated group. IL-1RA inhibits and modulates IL-1 responses
and SCF is also a pro-inflammatory inhibitor secreted by mast
cells to suppress the immune response including the suppression
of TNF-a and IL-6. This pattern of inhibitory cytokine secretion
is different to the cytokine profile measured in vaccinated adult
macaques where significantly increased production of Th2
cytokines such as IL-4, IL-5 and IL-15 was detected, suggesting
regulation of the proinflammatory response in a different manner.
This study demonstrates multiple differences between infant
rhesus macaques aged between six and 12 weeks of age and
young adult macaques aged between 3.7 and 5.2 years of age.
These differences correspond with distinct responses to the BCG
vaccine. As most animal models currently used to study TB
vaccine candidates rely on adult animals, which in our study
produced significantly higher amounts of cytokine following
BCG vaccination compared to macaques vaccinated in infancy,
understanding the immune responses generated when BCG is
given early in life is essential. Further investigation needs to be
done using neonatal and age appropriate models to understand
the protective efficacy afforded by the BCG vaccine and for the
development of improved vaccination strategies for deployment
in infants.
BCG provides protection to infants against severe forms of
TB, has been shown to give protection against other non-TB
pathogens, is associated with lower mortality in children, and can
improve the efficacy of other childhood vaccines (47). However,
it is widely believed that BCG protection is not durable past
adolescence (48). Our data show that BCG alters the frequencies
of classical monocytes, CD56+ NK cells and granulocytes present
in the periphery for at least three years after vaccination.
Although this change in host cell frequencies may not be
enough to provide continued protection against M.
tuberculosis, it may alter the immune response to booster
vaccinations. This needs to be considered when developingOctober 2021 | Volume 12 | Article 754589
Sarfas et al. Characterization of Infant BCG Vaccinationimproved vaccination strategies to understand whether BCG will
enhance, or mask, additional vaccinations given in later life.
Further studies investigating the effect that age at vaccination has
on the protective efficacy afforded by BCG as well as additional
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